Page 6 - 2022-24-中国全科医学

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2947·

·指南·共识·

慢性阻塞性肺疾病免疫调节治疗专家共识

《慢性阻塞性肺疾病免疫调节治疗专家共识》撰写组 扫描二维码
查看原文

【摘要】 慢性阻塞性肺疾病（简称慢阻肺）是我国重点防治的慢性呼吸系统疾病之一，深入探讨慢阻肺的免疫
发病机制并对其中的关键靶点进行干预可能为慢阻肺的防治提供新办法。基于目前临床常用的慢阻肺免疫调节剂相关
研究证据及具有免疫治疗作用的药物研发现状和趋势，《慢性阻塞性肺疾病免疫调节治疗专家共识》撰写组提出 4 条
推荐意见：（1）细菌溶解产物、磷酸二酯酶抑制剂、大环内酯类药物等生物、化学制剂均可通过增强机体免疫功能
和提高免疫细胞活性而发挥对慢阻肺的免疫调节作用；（2）针对流感病毒、肺炎球菌感染等进行疫苗接种可预防慢
阻肺急性加重、降低患者死亡率；（3）他汀类药物及维生素 D 等具有免疫调节作用，对慢阻肺可能有一定的治疗作用，
但二者在慢阻肺中的应用证据较少且存在一定不良反应，仍需进一步积累证据；（4）中医药复方及虫草制剂或可通
过调节机体免疫功能、提高免疫细胞活性改善慢阻肺稳定期患者生活质量，减少急性加重。本专家共识旨在进一步推
动我国慢阻肺免疫调节治疗的临床实践。
【关键词】 肺疾病，慢性阻塞性；慢性阻塞性肺疾病；免疫调节；药理作用分子作用机制；专家共识
【中图分类号】 R 563.9 【文献标识码】 A DOI：10.12114/j.issn.1007-9572.2022.0384
《慢性阻塞性肺疾病免疫调节治疗专家共识》撰写组 . 慢性阻塞性肺疾病免疫调节治疗专家共识［J］. 中国全科
医学，2022，25（24）：2947-2959.［www.chinagp.net］
Writing Group for the Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease. Expert
Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease［J］. Chinese General Practice，2022，
25（24）：2947-2959.

Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease Writing Group for the
Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease
*
Corresponding author：CHEN Yahong，Chief physician；E-mail：chenyahong@vip.sina.com
【Abstract】 China has attached importance to the prevention and treatment of chronic obstructive pulmonary disease
（COPD），a major chronic respiratory disease. An in-depth discussion of the immunopathogenesis of COPD and intervening
the identified key targets may be new ideas for the prevention and treatment of COPD. Based on the relevant evidence of commonly
used immunomodulatory agents for COPD，and the status and trend of development of immunomodulators for COPD，the
Writing Group for the Expert Consensus of Immunemodulatory Therapies for Chronic Obstructive Pulmonary Disease proposed the
following four recommendations for treating COPD with immunomodulatory therapies：（1）bacterial lysates，phosphodiesterase
inhibitors，macrolides and other biological and chemical agents have immunomodulatory efects on COPD by enhancing immune
function and immune cell activity；（2）vaccination against influenza and pneumococcal infection could reduce the probability
of acute exacerbation of COPD and mortality；（3）statins and vitamin D may be partially effective in COPD owing to their
immunomodulatory actions，but need to be verified further due to quite insufficient relevant evidence and reported adverse
reactions；（4）Chinese medicine compound and Cordyceps preparations may improve the quality of life and reduce the
probability of acute exacerbationsin patients with stable COPD by regulating immune function and improving immune cell activity.
The main purpose of this consensus is to greatly promote the clinical treatment of COPD using immunomodulatory therapies in
China.
【Key words】 Pulmonary disease，chronic obstructive；Chronic obstructive pulmonary disease；Immunomodulation；
Molecular mechanisms of pharmacological action；Expert consensus

基金项目：国家自然科学基金资助项目（82090013，82090014）；首都卫生发展科研专项项目（首发 2020-2Z-40917）
国际实践指南注册平台注册号：IPGRP-2022CN267
*
通信作者：陈亚红，主任医师；E-mail：chenyahong@vip.sina.com
本文数字出版日期：2022-06-27